List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 774 studies with search of: vaccination
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
Condition: Meningococcal Infections
Interventions: Biological: rMenB and concomitantly routine infant vaccinations;   Biological: rMenB and routine infant vaccinations;   Biological: Routine infant vaccines
2 Recruiting Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: 1a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 1b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 2a - Routine infant vaccinations and rMenB+OMV NZ;   Biological: 2b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations;   Biological: 4a- rMenB+OMV NZ and routine infant vaccinations;   Biological: 4b - rMenB+OMV NZ and routine infant vaccinations
3 Recruiting Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: rMenB+OMV NZ with routine vaccinations;   Biological: rMenB+OMV NZ;   Biological: two doses of rMenB+OMV NZ
4 Recruiting Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Conditions: HPV16+;   Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions: Biological: DNA vaccination;   Device: Gene gun vaccine;   Biological: intramuscular vaccination;   Biological: intra-lesional vaccine administration;   Procedure: therapeutic resection of the lesion
5 Recruiting Characterization of Humoral and Cellular Immunity of Low and High-Responders After Tick-Borne Encephalitis (TBE) Vaccination
Condition: Tick-Borne Encephalitis
Intervention: Biological: TBE vaccination and influenza vaccination
6 Recruiting Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY + Concomitant Vaccination;   Biological: 1 dose MenACWY + Concomitant Vaccination;   Biological: MenC (12 Month) + Concomitant Vaccination (12 Month)
7 Completed Influenza Vaccination in the Emergency Department
Condition: Influenza
Interventions: Drug: Influenza Vaccination;   Behavioral: Education and referral
8 Recruiting Study to Evaluate Impact of School-Based Influenza Vaccination on School Populations
Condition: Influenza
Intervention: Biological: School-based influenza vaccination program
9 Active, not recruiting Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine
Condition: Influenza
Interventions: Biological: Vaccination with Fluval P and Fluval AB influenza vaccines;   Biological: Vaccination with Fluval P monovalent influenza vaccine
10 Completed Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Biological: recombinant human Growth Hormone;   Biological: Vaccination;   Drug: HAART
11 Enrolling by invitation Effects of Different Anti-Rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar®
Conditions: Rheumatoid Arthritis;   Spondylarthropathy
Intervention: Biological: Prevenar vaccination
12 Active, not recruiting Safety and Tolerability of and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving Anti-HIV Treatment
Condition: HIV Infections
Interventions: Biological: LC002 standard vaccination;   Biological: LC002 high-dose vaccination;   Biological: LC002 placebo vaccination
13 Recruiting Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
Condition: Melanoma
Intervention: Biological: autologous dendritic cell vaccination
14 Active, not recruiting Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1);   Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2);   Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3);   Biological: Routine vaccination;   Biological: Meningococcal group C
15 Recruiting TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Biological: T cell vaccination
16 Completed Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study
Condition: Coronary Artery Disease
Interventions: Biological: Influenza vaccination: Influvac (SolvayPharma);   Biological: placebo influenza vaccine
17 Completed Long-Term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
Condition: Rotavirus Gastroenteritis
Intervention: Biological: Rotarix (primary vaccination study)
18 Completed Vaccination of Patients With Stage IV Melanoma With Dendritic Cells
Conditions: Melanoma;   Neoplasm Metastasis
Intervention: Biological: Dendritic cell vaccination
19 Completed Influenza Vaccination and Oral Anticoagulant Therapy
Conditions: Anticoagulants;   Influenza Vaccines
Intervention: Drug: Influenza vaccination
20 Recruiting Randomized Study of Not Giving Diphteria-Tetanus-Pertussis Vaccination With or After Measles Vaccination
Conditions: Mortality;   Hospitalization;   Adverse Events
Intervention: Biological: DTP3+OPV3 and MV versus OPV3 and MV or DTP4+OPV4 versus OPV4

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services